Caribou Biosciences, Inc. Common Stock (CRBU)

Price$2.29

Favorite Metrics

Price vs S&P 500 (26W)-20.39%

Price vs S&P 500 (4W)8.15%

Market Capitalization$212.60M

All Metrics

Book Value / Share (Quarterly)$1.28

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-6.95%

Cash Flow / Share (Quarterly)$-1.18

Price vs S&P 500 (YTD)34.23%

Net Profit Margin (TTM)-1327.40%

EPS (TTM)$-1.59

10-Day Avg Trading Volume1.40M

EPS Excl Extra (TTM)$-1.59

Revenue Growth (5Y)-2.02%

EPS (Annual)$-1.59

ROI (Annual)-121.24%

Net Profit Margin (5Y Avg)-906.06%

Cash / Share (Quarterly)$1.46

Revenue Growth QoQ (YoY)89.74%

ROA (Last FY)-84.47%

Revenue Growth TTM (YoY)11.66%

EBITD / Share (TTM)$-1.55

ROE (5Y Avg)-51.64%

Operating Margin (TTM)-1411.43%

Cash Flow / Share (Annual)$-1.18

P/B Ratio1.74x

P/B Ratio (Quarterly)1.22x

Net Income / Employee (Annual)$-2

EV / Revenue (TTM)17.94x

Net Interest Coverage (TTM)-16978.50x

ROA (TTM)-68.50%

EPS Incl Extra (Annual)$-1.59

Current Ratio (Annual)5.71x

Quick Ratio (Quarterly)5.60x

3-Month Avg Trading Volume1.21M

52-Week Price Return200.10%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.50

P/S Ratio (Annual)19.05x

Asset Turnover (Annual)0.06x

52-Week High$3.54

Operating Margin (5Y Avg)-972.94%

EPS Excl Extra (Annual)$-1.59

CapEx CAGR (5Y)33.54%

26-Week Price Return-11.65%

Quick Ratio (Annual)5.60x

13-Week Price Return36.65%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.71x

Enterprise Value$200.242

Revenue / Share Growth (5Y)-11.33%

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1332.33%

Cash / Share (Annual)$1.46

3-Month Return Std Dev77.33%

Net Income / Employee (TTM)$-2

ROE (Last FY)-121.24%

Net Interest Coverage (Annual)-852.54x

EPS Basic Excl Extra (Annual)$-1.59

Receivables Turnover (TTM)6.51x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.59

Receivables Turnover (Annual)6.51x

ROI (TTM)-91.52%

P/S Ratio (TTM)19.05x

Pretax Margin (5Y Avg)-906.19%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$4.93

Price vs S&P 500 (52W)165.00%

Year-to-Date Return38.36%

5-Day Price Return12.82%

EPS Normalized (Annual)$-1.59

ROA (5Y Avg)-39.48%

Net Profit Margin (Annual)-1327.40%

Month-to-Date Return15.79%

Cash Flow / Share (TTM)$-1.36

EBITD / Share (Annual)$-1.55

Operating Margin (Annual)-1411.43%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-51.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.59

P/TBV (Quarterly)1.26x

P/B Ratio (Annual)1.22x

Pretax Margin (TTM)-1332.33%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)33.78%

Beta2.50x

Revenue / Share (TTM)$0.12

ROE (TTM)-91.52%

52-Week Low$0.71

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.29

4.27

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CRBUCaribou Biosciences, Inc. Common Stock	19.05x	11.66%	—	—	$2.29
AMGNAmgen Inc	5.20x	9.95%	73.30%	2.93%	$350.16
GILDGilead Sciences Inc	5.71x	2.40%	78.83%	133.64%	$135.87
ARGXargenx SE American Depositary Shares	12.59x	89.56%	150.91%	—	$834.45
BNTXBioNTech SE American Depositary Share	9.06x	-11.81%	84.21%	—	$105.19
BIIBBiogen Inc. Common Stock	2.72x	2.22%	75.69%	-18.77%	$183.34
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$54.59
NBIXNeurocrine Biosciences Inc	4.64x	21.45%	98.18%	2.31%	$131.59
EXELExelixis Inc	4.89x	6.85%	96.39%	31.10%	$43.61
TECHBio-Techne Corp.	7.72x	1.64%	66.60%	-20.58%	$60.58
IBRXImmunityBio, Inc. Common Stock	74.42x	668.31%	99.34%	—	$8.20

About

Caribou Biosciences is a clinical-stage CRISPR biopharmaceutical company developing next-generation cell therapies using its proprietary chRDNA platform. The company focuses on creating allogeneic CAR-T and CAR-NK cell therapies designed to treat patients with serious diseases. Caribou's genome-editing approach aims to overcome existing limitations in cell-based cancer therapeutics.